Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/12—Drugs for disorders of the urinary system of the kidneys
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
  • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
  • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
  • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

• the present invention relates to a method for producing an acid addition salt of a polyacidic base compound or a water adduct thereof, which can easily add a desired number of acids to the polyacidic base compound.
• VLDL very low density riboprotein
• ACAT Inhibitors include hyperlipidemia, arteriosclerosis, facial and cerebral arteriosclerosis, cerebrovascular disease, ischemic heart disease, coronary atherosclerosis, renal sclerosis, atherosclerotic nephrosclerosis, atherosclerotic kidney Treatment and prevention of various diseases such as sclerosis, malignant renal sclerosis, ischemic bowel disease, acute mesenteric vaso-occlusion chronic intestinal angina, ischemic colitis, aortic cancer, and atherosclerosis obliterans (AS0) It is expected to be applicable to many countries, and a lot of research and development is underway.
• piperazine derivatives useful as ACAT inhibitors for example, 2- [4-1- [2- (benzimidazo-l-2-ylthio) ethyl] pidazine-11-yl] -1N— [2, 4-Bis (methylthio) -1-6-methyl-3-pyridyl] acetamide crystallizes in the form of a free base, but its crystals are inhomogeneous and have poor physical stability and low water solubility. It has problems such as extremely low.
• Such polyacidic base compounds are generally added with an acid to improve oral absorbability and the like, and the problem can be solved by using the compound as an acid addition salt.
• the water solubility and oral absorption of acetoamide can be significantly improved by using excess hydrochloric acid to make tetrahydrochloride / 2-hydrate adduct.
• the addition number of the acid affects the properties of the acid addition salt of the polyacidic base compound formed, and the above-mentioned tetrahydrochloride and dihydrate adduct has poor crystallinity by powder X-ray diffraction measurement. Problems such as easy dehydration and dehydrochlorination caused by differential thermal analysis and high hygroscopicity observed by a hygroscopicity test are pointed out. In addition, there may be problems such as residual acid used excessively and metal corrosion of tableting machines and aluminum sheets caused by the highly acidic salt of tetrahydrochloride, which may affect the formulation and stability of the formulation. Is done.
• an object of the present invention is to provide a production method capable of easily and easily obtaining a desired number of acid addition salts of an acid addition salt of a polyacidic base compound or a water addition product thereof.
• the present inventors have conducted intensive studies in view of the above circumstances, and have found that by reacting a polyacidic base compound with a pyridine acid salt formed from pyridine and an acid, a desired number of basic sites more strongly than pyridine can be obtained. It has been found that an acid addition salt of a polyacidic base compound to which an acid has been added can be easily produced.
• acid addition salts of various piperazine derivatives produced by this method for example, 2- [4- [2- (benzimidazo-l-2-ylthio) ethyl] piperazine-1-yl] 1-N- [ 2,4-bis (methylthio) 16-methyl-3-pyridyl] acetamide 'monohydrochloride ⁇ 0.9 water adduct has high crystallinity, no hygroscopicity, and changes in weight due to dehydration, dehydrochlorination, etc. It was found to be a good acid addition salt without the problem of polymorphism, without the problem of polymorphism, and without being affected by the residual hydrochloric acid, and found to be useful as a drug substance. Ming completed.
• the present invention provides a method for producing an acid addition salt of a polyacidic base compound or a water adduct thereof, which comprises reacting a polyacidic basic compound having a more basic site than pyridine with an acid salt of pyridine. Is what you do.
• the present invention relates to 2- [4- [2- [benzimidazole-2-ylthio) ethyl] piperazine-11-yl] -N- [2,4-bis (methylthio) _6-methyl L-3-pyridyl] acetamide 'monohydrochloride or its water adduct, 2- [4- [2- (5,6-difluorobenzimidazol-2-ylthio) ethyl] piperazin-1-yl]- N- [2,4-bis (2,2,2-trifluoroethoxy) -1-6-methyl-3-pyridyl] acetamide monohydrochloride or its water adduct, 21-
• the production method of the present invention can easily produce a salt obtained by adding a desired number of acids to a polyacidic base compound. According to this production method, not only control of the number of addition acids, but also stable production of acid addition salts of acid-labile polyacidic base compounds is possible.
• FIG. 3 is a view showing powder X-ray diffraction of acetoamide ⁇ monohydrochloride ⁇ 0.9 water adduct.
• FIG. 9 shows the results of TG-DSC measurement of —pyridyl] acetoamide ⁇ monohydrochloride ⁇ 0.9 water adduct.
• FIG. 2 is a view showing a powder X-ray diffraction of a lysyl] acetoamide ⁇ tetrahydrochloride ⁇ dihydrate adduct.
• Figure 4 shows 2- [4- [2- (benzimidazol-2-ylthio) ethyl] pirazine-1-1-yl] -N- [2,4_bis (methylthio) -1-6-methyl-3
• FIG. 9 shows the results of TG-DSC measurement of —pyridyl] acetoamide ⁇ tetrahydrochloride ⁇ dihydrate adduct.
• FIG. 3 is a view showing powder X-ray diffraction of acetoamide disulfate '1.5 water adduct.
• FIG. 9 shows the results of TG-DSC measurement of pyridyl] acetoamide ⁇ disulfate ⁇ 1.5 water adduct.
• FIG. 2 is a view showing a powder X-ray diffraction of a pyridyl] acetoamide.monosulfate ⁇ '4 water adduct.
• FIG. 4 is a graph showing the results of TG-DSC measurement of lysyl] acetoamide ⁇ monosulfate ⁇ tetrahydrate adduct.
• FIG. 3 is a view showing a powder X-ray diffraction of lysyl] acetoamide monosulfate.
• FIG. 3 is a view showing the results of TG-DSC measurement of acetoamide monosulfate.
• FIG. 3 is a drawing showing powder X-ray diffraction of [pyridyl] acetoamide dimaleate.
• Figure 12 shows 2- [4- [2- (benzimidazol-2-ylthio) ethyl] piperazine-1-1-yl] -1-N- [2,4-bis (methylthio) _6_methyl-3-pyridyl
• FIG. 3 is a view showing the results of TG-DSC measurement of acetoamide dimaleate.
• FIG. 3 shows the results of TG-DTA measurement of bis (2,2,2-trifluoroethoxy) -6-methyl-3-pyridyl] acetamide and its monohydrochloride.
• FIG. 3 shows the results of TG-DTA measurement of (6-ethoxy-3-6-pyridyl) acetoamide and its dihydrochloride.
• Figures 17 and 18 show 2- [4-I- [2- (benzoxazole-2-ylthio) ethyl] piperazine-1-yl] -N- [2,4-bis (2,2,2
• FIG. 3 shows the results of TG-DTA measurement of [trifluroyloxy) -6-methyl-3-pyridyl] acetoamide and its monohydrochloride.
• FIGS. 19 and 20 show 2- [4-1-1 [2- (benzthiazo-l-2-ylthio) X tyl] piperazine-1-yl] -1-N— [2,6-dimethyl-4-trifluorotrifluoromethyl—3—
• FIG. 3 shows the results of TG-DTA measurement of [pyridyl] acetoamide and its dihydrochloride.
• FIG. 21 and 22 show 2- [4- [2- (5-trifluoromethylbenzoxazol-2-ylthio) ethyl] piperazine-1-yl] -N- [2,4-bis
• FIG. 3 shows the results of TG-DTA measurement of (methylthio) -6-methyl-3-pyridyl] acetoamide and its monohydrochloride.
• FIG. 23 and 24 show 2- [4- [2- (Benzoxazolyl-2-ylthio) ethyl] piperazine-11-yl] -N- [2- (2-methoxyethoxy) -4- (2 FIG. 2 shows the results of TG-DTA measurement of [2,2,2-trifluoroethoxy) -16-methyl_3_pyridyl] acetamide and its monohydrochloride.
• the polyacidic base compound used in the present invention is a compound having one or more basic sites stronger than pyridine, such as a piperazino group, a tertiary amino group, a secondary amino group, and a primary amino group.
• a plurality of nitrogen-containing compounds in the same molecule is preferably a nitrogen-containing organic compound, and more preferably a piperazine derivative.
• X represents one NH—, an oxygen atom or a sulfur atom
• Y ⁇ 2 and ⁇ 3 each independently represent hydrogen, octogen.
• a lower alkyl group or a lower alkyl group, R ⁇ R 2 and R 3 each independently represent hydrogen, halogen, a lower alkyl group, a lower haloalkyl group, a lower alkylthio group, a lower haloalkoxy group or a lower alkoxyalkoxy group, and 1 represents an integer of 1-2.
• m represents an integer of 2 to 4, and n represents an integer of:! To 3.
• the term "lower" indicates that the number of carbon atoms is 1 to 5, but preferably 1 to 3.
• X represents one NH—, oxygen atom or sulfur atom
• Y 1 and Y 2 each independently represent hydrogen, halogen or trifluoromethyl group, and! ⁇ And! ⁇ Are each independent.
• the acid salt of pyridine used in the present invention is a salt of pyridine with an inorganic acid or an organic acid
• the acid that forms a salt with pyridine is not particularly limited, but hydrochloric acid, sulfuric acid, nitric acid, phosphoric acid, sulfurous acid , Nitric acid, hydrobromic acid, hydroiodic acid, and other inorganic acids; and acetic acid, butyric acid, stearic acid, and other fatty acids; oxalic acid, maleic acid, succinic acid, fumaric acid, and other polybasic acids; Hydroxycarboxylic acids such as tartaric acid, malic acid, mandelic acid, salicylic acid, pamoic acid, pantothenic acid, and dalconic acid; sulfonic acids such as ethanedisulfonic acid, benzenesulfonic acid, paratoluenesulfonic acid, and methanesulfonic acid; glutamic acid, and aspara
• the acid is preferably hydrochloric acid, sulfuric acid, maleic acid, fumaric acid, tartaric acid, malic acid, citric acid, methyl sulfonic acid, and the like, more preferably hydrochloric acid, sulfuric acid, and maleic acid, and particularly preferably hydrochloric acid.
• the pyridine acid salt may be used in either crystalline or non-crystalline form.
• the pyridine acid salt can be obtained by theoretically reacting pyridine with an acid in an equivalent amount, but specifically, in an anhydrous or aqueous organic solvent. It is preferable to use pyridine in an excess amount to the acid, and it is preferable to use 1.0 to 1.5 times, more preferably 1.0 to 1.2 times, the equivalent of pyridine to the acid.
• the resulting pyridine acid salt can be purified by an ordinary crystallization method using a solvent or the like.
• the amount of the pyridine acid salt usually used is the same as the number of moles of the acid added to 1 mol of the polyacidic base compound.
• An acid salt of pyridine that can supply an acid of pyridine is used. Specifically, depending on the type and amount of the solvent to be used, the acid can be supplied in an amount of 1.0 to 3.0 times, preferably 1.0 to 2.5 times the molar number of the acid to be added. It is preferred to use an amount of the acid salt of pyridine.
• an acid addition salt of a polyacidic base compound is produced using a non-crystalline acid salt of pyridine
• an acid added to 1 mol of the polyacidic base compound to the polyacidic base compound in an anhydrous or aqueous organic solvent is used.
• the method for producing the acid addition salt of the polyacidic base compound is as follows: the pyridine acid salt required for the amount of the acid to be added to the polyacidic base compound is added at 0 to 120 ° (: more preferably at room temperature to 100 ° C) in an organic solvent. C, particularly preferably, when heated and dissolved at the reflux temperature of the organic solvent used, salt exchange occurs between the polyacidic base compound and the acid salt of pyridine to form an acid addition salt of the polyacidic base compound.
• organic solvent used herein examples include lower alcohols such as methanol, ethanol and isopropanol, ethers such as dioxane and tetrahydrofuran, acetone, and acetonitrile.
• a mixed solvent obtained by adding water to an organic solvent can be used.
• the type and amount of the solvent used here are not particularly limited, but it is desirable to appropriately select the type and amount that maximize the yield of the acid addition salt of the polyacidic base compound.
• the resulting acid addition salt of the polyacidic base compound or its water adduct is obtained by allowing the mixture to stand for 0.5 to 24 hours with stirring, if necessary, and then collecting the precipitated crystals.
• the acid salt of pyridine used in the present invention relatively weakens the acidity of the acid used, when the educt of the polyacidic base compound is unstable with respect to the acid, addition of a strong acid by a conventional method, etc.
• the problems such as decomposition of the drug substance and generation of impurities due to a local decrease in pH in the system due to aging are remarkably alleviated.
• the production method of the present invention is directed to an acid addition salt of the piperidine derivative
• 2- [4- [2- (benzimidazo-l-l-ylthio) ethyl] piperazine_1-yl] -N- [2,4-bis (methylthio) 1 6_Methyl-3_pyridyl] acetoamide ⁇ monohydrochloride ⁇ 0.9 water adduct has high crystallinity, has no hygroscopic property, does not involve weight change due to dehydration, dehydrochlorination, etc., and has thermal stability It is a preferable acid addition salt because it is excellent in crystallinity, does not cause the problem of polymorphism, and is not affected by the residual hydrochloric acid.
• the precipitated crystals were collected by filtration, washed successively with a mixed solvent of methanol-ether (1: 1) (500 mL) and ether (500 mL), and dried under reduced pressure at room temperature for 3 hours to give the title compound (133.54 g, 73.0%). ) Was obtained as colorless crystals.
• ⁇ -Band R (400MHz, DMS0-d 6 ) ⁇ : 2.40 (6 ⁇ , s), 2.45 (3H, s), 2.80-3.72 (14H, m), 6.92 (1H, m), 7.11-7.18 (2H, m), 7.43-7.53 (2H, m), 9.38 (1H, br s).
• Fig. 3 shows the powder X-ray diffraction pattern of acetoamide, tetrahydrochloride and dihydrate
• Fig. 4 shows the results of TG-DSC measurement.
• FIG. 6 shows the results of 2- [4-1- [2- (benzimidazolu-2-ylthio) ethyl] piperazine-1-yl] — N— [2,41-1
• Figure 7 shows the powder X-ray diffraction pattern of bis (methylthio) 1-6-methyl-3_pyridyl] acetamide 'monosulfate / 4-hydrate adduct
• Fig. 8 shows the TG-DSC measurement results
• FIG. 11 shows a powder X-ray diffraction pattern of the acid salt, and FIG. table 1
• Thermal stability The purity of the acid addition salt of the polyacidic base compound stored at 80 ° C for 10 days was determined by HPLC before storage. However, disulfate ⁇ 1.5 water adduct and dimaleate were stored at 60 ° C for 7 days and then at 80 ° C for 10 days.
• Hygroscopicity Changes in weight after storage for 4 days under conditions of 25 ° C and 83% relative humidity were measured.
• Figure 13 and Figure 14 show 2- [4-1-1 [2- (5,6-difluorobenzimidazolu-2-ylthio) ethyl] piperazine-1-yl] -N- [2,4-bis Shows the results of TG (thermogravimetric analysis)-DTA (differential thermal analysis) measurement of (2,2,2-trifluoroethoxy) 16-methyl-3-pyridyl] acetamide and its monohydrochloride You.
• This hydrochloride (250 mg) was suspended in water (2.5 mL) and heated to 80 ° C to dissolve. After cooling the reaction solution to room temperature, the crystals were collected by filtration, washed with water (1 mLX2), and dried under reduced pressure under heating at 50 ° C for 7 hours to give the title compound.
• Figures 15 and 16 show 2- [4- [2- (benzimidazo-l-2-ylthio) ethyl] piperazine- 1-yl] -N- [2,4-bis (2,2,2- The result of TG-DTA measurement of (trifluoroethoxy) -6-methyl-3-pyridyl] acetoamide and its dihydrochloride is shown.
• Figures 17 and 18 show 2 -— [4- [2- (Benzoxazolyl-2-ylthio) ethyl] piperazine-1-yl] -N- [2,4-bis (2,2,2 —Trifluoroethoxy) -1-6-methyl-3-pyridyl] acetamide and its monohydrochloride
• IR (KBr) cur 1 3431, 1690, 1591, 1508, 1454, 1274, 1169, 1139.
• 2,6-Dimethyl-14-trifluoromethylpyridine-3 -methyl ribonate (23.30 g, 99.9 t ol) was dissolved in ethanol (50 mL), and a 5 mol / L aqueous hydroxide solution (50 mL / L) was added. mL, 250 tmol) and heated to reflux for 2 days. After allowing the reaction solution to cool to room temperature, concentrated hydrochloric acid (15 mL) was added thereto, and the residue obtained by concentration under reduced pressure was azeotroped three times with ethanol and toluene. The obtained residue was filtered after suspending by heating with ethanol, and the filtrate was concentrated under reduced pressure. After the obtained residue was azeotroped twice with toluene, ether was added and the mixture was collected by filtration to give the title compound (25.24 g, 99) as a colorless powder.
• N, N-Dimethylaniline (10.80 g, 89.12 Awake 01) was added and stirred in an ice bath, and a solution of bromoacetyl bromide (15.52 g, 76.90 thigh 01) in dichloromethane (40 mL) was added dropwise. Then, the mixture was stirred at room temperature for 2 hours.
• FIG. 9 shows the results of TG-DTA measurement of [pyridyl] acetoamide and its dihydrochloride.
• Figures 21 and 22 show 2_ [4- [2- (5-trifluoromethylbenzoxazol-2-ylthio) ethyl] piperazine-11-yl] -N- [2,4 One screw
• FIG. 4 shows the results of TG-DTA measurement of (methylthio) [1-6-methyl-3-pyridyl] acetoamide and its monohydrochloride.
• IR (KBr) cm— 1 3427, 1685, 1501, 1437, 1327, 1143, 1123.
• Figures 23 and 24 show 2- [4- [2- [benzoxazole-2-ylthio) ethyl] pirazazine-1-yl] — N— [2- (2-methoxyethoxy) -1

Priority Applications (18)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=32923406

Family Applications (1)

Country Status (21)

Cited By (12)

Families Citing this family (1)

Citations (1)

Family Cites Families (6)

• 2004
  • 2004-02-25 MY MYPI20040608A patent/MY140618A/en unknown
  • 2004-02-27 NZ NZ541716A patent/NZ541716A/en not_active IP Right Cessation
  • 2004-02-27 ES ES04715495T patent/ES2384517T3/es not_active Expired - Lifetime
  • 2004-02-27 KR KR1020057015048A patent/KR101106127B1/ko not_active IP Right Cessation
  • 2004-02-27 CN CN2004800052621A patent/CN1753886B/zh not_active Expired - Fee Related
  • 2004-02-27 EA EA200501379A patent/EA009045B1/ru not_active IP Right Cessation
  • 2004-02-27 AU AU2004215523A patent/AU2004215523B2/en not_active Ceased
  • 2004-02-27 CA CA2516822A patent/CA2516822C/en not_active Expired - Fee Related
  • 2004-02-27 BR BRPI0407908-6A patent/BRPI0407908A/pt not_active Application Discontinuation
  • 2004-02-27 WO PCT/JP2004/002375 patent/WO2004076441A1/ja active Search and Examination
  • 2004-02-27 MX MXPA05009129A patent/MXPA05009129A/es active IP Right Grant
  • 2004-02-27 TW TW100135167A patent/TWI374136B/zh not_active IP Right Cessation
  • 2004-02-27 AT AT04715495T patent/ATE554083T1/de active
  • 2004-02-27 JP JP2005502951A patent/JP4594863B2/ja not_active Expired - Fee Related
  • 2004-02-27 CN CN201210189482.0A patent/CN102702171B/zh not_active Expired - Fee Related
  • 2004-02-27 EP EP04715495A patent/EP1598346B1/en not_active Expired - Lifetime
  • 2004-02-27 US US10/545,200 patent/US7750150B2/en not_active Expired - Fee Related
  • 2004-02-27 PL PL378292A patent/PL378292A1/pl not_active IP Right Cessation
  • 2004-02-27 DK DK04715495.0T patent/DK1598346T3/da active
  • 2004-02-27 TW TW093105174A patent/TWI355384B/zh not_active IP Right Cessation
• 2005
  • 2005-08-04 IL IL170093A patent/IL170093A/en not_active IP Right Cessation
  • 2005-08-12 IS IS7978A patent/IS7978A/is unknown
  • 2005-09-02 NO NO20054100A patent/NO331272B1/no not_active IP Right Cessation
• 2010
  • 2010-04-16 US US12/762,111 patent/US8518936B2/en not_active Expired - Fee Related
  • 2010-07-15 JP JP2010160354A patent/JP5180998B2/ja not_active Expired - Fee Related

Patent Citations (1)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events